the pharmacokinetics ( distribution , metabolism , bioavailability , excretion ) and toxicity ( acute and subacute toxicity , mutagenicity ) of a superparamagnetic iron oxide preparation ( ami-25 ) , currently used in clinical trials , were evaluated by 59fe radiotracer studies , measurements of relaxation times , the ability to reverse iron deficiency anemia , histologic examination , and laboratory parameters .
C0025519
metabolism
C0221102
excretion